Search results for "Liver cirrhosis."

showing 10 items of 598 documents

In vivo confocal laser laparoscopy allows real time subsurface microscopy in animal models of liver disease.

2007

Background/Aims Histopathology is essential in the diagnostic workup of most liver diseases. However, biopsy sampling might carry risks, is subject to sampling error, and does not provide dynamic tissue imaging. Therefore a newly developed miniaturised confocal probe was evaluated for in vivo microscopic imaging in rodent models of human liver diseases. Methods The handheld laparoscopy probe used a 488nm single line laser for fluorophore excitation. Optical slice thickness was 7μm, lateral resolution 0.7μm. Imaging depth was 0–250μm below the tissue surface. Imaging using different fluorescent staining protocols was performed in healthy mice, IFNγ- and IL-12-induced hepatitis, after bile du…

LeptinLiver CirrhosisPathologymedicine.medical_specialtyConfocalBiologylaw.inventionLiver diseaseMiceIn vivoConfocal microscopylawBiopsymedicineAnimalsAcriflavineLigationFluorescent DyesCommon Bile DuctMice KnockoutMicroscopy ConfocalHepatologymedicine.diagnostic_testCommon bile ductLiver DiseasesFatty liverDextransmedicine.diseaseMice Inbred C57BLDisease Models Animalmedicine.anatomical_structureLiverCytokinesLaparoscopyChemical and Drug Induced Liver InjuryPreclinical imagingFluorescein-5-isothiocyanateJournal of hepatology
researchProduct

Phosphate Groups in the Lipid A Moiety Determine the Effects of LPS on Hepatic Stellate Cells: A Role for LPS-Dephosphorylating Activity in Liver Fib…

2020

Alkaline phosphatase (AP) activity is highly upregulated in plasma during liver diseases. Previously, we demonstrated that AP is able to detoxify lipopolysaccharide (LPS) by dephosphorylating its lipid A moiety. Because a role of gut-derived LPS in liver fibrogenesis has become evident, we now examined the relevance of phosphate groups in the lipid A moiety in this process. The effects of mono-phosphoryl and di-phosphoryl lipid A (MPLA and DPLA, respectively) were studied in vitro and LPS-dephosphorylating activity was studied in normal and fibrotic mouse and human livers. The effects of intestinal AP were studied in mice with CCL4-induced liver fibrosis. DPLA strongly stimulated fibrogenic…

LipopolysaccharidesLiver CirrhosisMale0301 basic medicinemedicine.medical_specialtyLipopolysaccharideNitric OxideArticleLipid AMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDownregulation and upregulationInternal medicinemedicineAnimalsMacrophagePhosphorylationlipid Alcsh:QH301-705.5liver fibrosisMice Inbred BALB CInterleukin-6MacrophageslipopolysaccharideBiological activityGeneral MedicineIn vitroRatsUp-RegulationRAW 264.7 Cells030104 developmental biologyEndocrinologyLiverchemistrylcsh:Biology (General)Hepatic stellate cellAlkaline phosphatase030211 gastroenterology & hepatologylipids (amino acids peptides and proteins)hepatic stellate cellsalkaline phosphatase
researchProduct

Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways

2012

Background & Aims: miR-224 is up-regulated in human HCCs as compared to both paired peri-tumoral cirrhotic tissues and cirrhotic livers without HCC. Here, we have cloned the miR-224 regulatory region and characterized its transcriptional regulation by the NFκB-dependent inflammatory pathways. Methods: Mature miRNA expression was evaluated by a 2 step stem-loop real-time RT-PCR. The recruitment of polymerase II and transcription factors on the pre-miR-224 promoter has been assessed by ChIPSeq and ChIP. Results: We found miR-224 levels strongly up-regulated in both peri-tumoral cirrhotic livers and HCC samples as compared to normal livers. In silico analysis of the putative miR-224 promoter r…

LipopolysaccharidesLiver CirrhosisMaleCarcinoma HepatocellularTranscription GeneticLiver CirrhosiLipopolysaccharideBiologyCell MovementCell Line TumormicroRNATranscriptional regulationHumansNF kappa BHCCmir-224; nfκb; hcc; mirnas; transcriptionTranscription factorLymphotoxin-alphamiRNAAgedHepatologymiRNAs; HCC; miR-224; Transcription; NF kappa BTumor Necrosis Factor-alphaLiver NeoplasmsNF-kappa BMicroRNAmiR-224HCCSMiddle AgedNFKB1Up-RegulationMicroRNAsIκBαLiverLiver NeoplasmCase-Control StudiesImmunologymiRNAsCancer researchTumor necrosis factor alphaFemaleSignal transductionCase-Control StudieTranscriptionNFκBHumanSignal Transduction
researchProduct

Circulating levels of 3-hydroxymyristate, a direct quantification of endotoxaemia in noninfected cirrhotic patients

2019

IF 4.5; International audience; Background & AimsThe quantification of lipopolysaccharide (LPS) in biological fluids is challenging. We aimed to measure plasma LPS concentration using a new method of direct quantification of 3‐hydroxymyristate (3‐HM), a lipid component of LPS, and to evaluate correlations between 3‐HM and markers of liver function, endothelial activation, portal hypertension and enterocyte damage.MethodsPlasma from 90 noninfected cirrhotic patients (30 Child‐Pugh [CP]‐A, 30 CP‐B, 30 CP‐C) was prospectively collected. The concentration of 3‐HM was determined by high‐performance liquid chromatography coupled with mass spectrometry.Results3‐HM levels were higher in CP‐C patien…

LipopolysaccharidesLiver CirrhosisMalemedicine.medical_specialtyCirrhosisLipopolysaccharidePilot ProjectsSeverity of Illness IndexGastroenterologyEndothelial activationendotoxaemia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk Factors3-HydroxymyristateInternal medicineHumansMedicinebacterial translocationHepatic encephalopathyChromatography High Pressure LiquidAgedHepatologybusiness.industrycirrhosislipopolysaccharideportal hypertensionMiddle Agedmedicine.diseaseEndotoxemia3. Good healthLogistic ModelschemistryHepatic Encephalopathy030220 oncology & carcinogenesisMultivariate AnalysisPortal hypertension[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemale030211 gastroenterology & hepatologyLiver function3-hydroxymyristatebusinessAcute Alcoholic HepatitisMyristic AcidsBiomarkersBlood Chemical Analysis
researchProduct

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

2020

The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, “positive criteria” to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD that is both comprehensive and simple, and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence …

Liver Cirrhosis0301 basic medicineCirrhosisDiagnostic criteriaCirrhosis; Diabetes; Diagnostic criteria; MAFLD; Metabolic; NAFLD; Obesity; Steatohepatitis[SDV]Life Sciences [q-bio]HISTOLOGIC FEATURESPROGRESSIONDiseaseTerminology0302 clinical medicineMedicine10. No inequalitySteatohepatitisNONALCOHOLIC STEATOHEPATITISFatty liverHIGH BLOOD-PRESSUREDiabetesHEALTHY OBESE3. Good healthPREVALENCECausalityCirrhosisDisease Progression030211 gastroenterology & hepatologymedicine.medical_specialtyConsensusMAFLDDIAGNOSIS03 medical and health sciencesMetabolic DiseasesTerminology as TopicDiabetes mellitusNAFLDMANAGEMENTHumansObesityIntensive care medicineHepatologybusiness.industryType 2 Diabetes MellitusNATURAL-HISTORYmedicine.diseaseFatty LiverClinical trial030104 developmental biologyDiabetes Mellitus Type 2MetabolicSteatohepatitisbusiness
researchProduct

Liver fibrosis: Direct antifibrotic agents and targeted therapies

2018

Liver fibrosis and in particular cirrhosis are the major causes of morbidity and mortality of patients with chronic liver disease. Their prevention or reversal have become major endpoints in clinical trials with novel liver specific drugs. Remarkable progress has been made with therapies that efficiently address the cause of the underlying liver disease, as in chronic hepatitis B and C. Highly effective antiviral therapy can prevent progression or even induce reversal in the majority of patients, but such treatment remains elusive for the majority of liver patients with advanced alcoholic or nonalcoholic steatohepatitis, genetic or autoimmune liver diseases. Moreover, drugs that would speed…

Liver Cirrhosis0301 basic medicineCirrhosisDiseaseChronic liver disease03 medical and health sciencesLiver diseaseTransforming Growth Factor betaFibrosisAnimalsHumansMedicineMolecular Targeted TherapyMolecular BiologyExtracellular Matrix ProteinsDDR1business.industrymedicine.disease3. Good healthBiomarker (cell)030104 developmental biologyDisease ProgressionCancer researchHepatic stellate cellbusinessSignal TransductionMatrix Biology
researchProduct

In vitro evidences of epithelial to mesenchymal transition in low cell-density cultured human fetal hepatocytes

2017

Abstract Culturing fetal hepatocytes in high cell-density allowed stabilization of the hepatocyte phenotype up to 8 weeks, including the maintenance of liver-specific functions. On the other hand, when cultured at low cell-density, fetal hepatocytes underwent morphological modifications and acquired fibroblastic morphology. Since a switch from E-cadherin to vimentin expression accompanied these changes, we hypothesized the occurrence of epithelial-to-mesenchymal transition when fetal hepatocytes were cultured at low cell-density. Changes in gene expressionsuch as up-regulation of fibrosis-related geneswere also observed, suggesting that the low cell-density culture system promoted the acqui…

Liver Cirrhosis0301 basic medicineEpithelial-Mesenchymal TransitionLiver fibrosisLiver fibrosisCell Culture TechniquesBiophysicsCell CountBiologyPrimary culturesBiochemistry03 medical and health sciencesFetal hepatocytesmedicineHumansEpithelial–mesenchymal transitionMolecular BiologyGeneCells CulturedEpithelial to mesenchymal transitionFetusTransition (genetics)Cell BiologyPhenotypeIn vitroCell biology030104 developmental biologymedicine.anatomical_structureLiverHepatocyteImmunologyHepatocytesBiochemical and Biophysical Research Communications
researchProduct

Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?

2016

Background: Iron overload and hepatitis C virus (HCV) infection together can lead to chronic liver damage in thalassemia major (TM) patients. Aims: We investigated viral, genetic, and disease factors influencing sustained virological response (SVR) after peg-interferon and ribavirin therapy in TM patients with HCV infection. Methods: We analyzed 230 TM patients with HCV infection (mean age 36.0 ± 6.3 years; 59.1% genotype 1; 32.2% genotype 2; 3.4% genotype 3; and 5.3% genotype 4; 28.7% carried CC allele of rs12979860 in IL28B locus; 79.6% had chronic hepatitis and 20.4% cirrhosis; 63.5% naive and 36.5% previously treated with interferon alone) treated in 14 Italian centers. Results: By mul…

Liver Cirrhosis0301 basic medicineMaleCirrhosisThalassemiaHepacivirusCirrhosis; Hepatitis C virus; IL28B polymorphisms; Iron liver overload; Peg-interferon; Ribavirin; Sustained virological response; Thalassemia major; Adult; Antiviral Agents; Drug Therapy Combination; Female; Heart Diseases; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Interleukins; Italy; Liver Cirrhosis; Logistic Models; Male; Multivariate Analysis; Polymorphism Single Nucleotide; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load; beta-Thalassemiamedicine.disease_causeGastroenterologychemistry.chemical_compound0302 clinical medicineRetrospective StudieThalassemia majorMultivariate AnalysiGastroenterologyBeta thalassemiaHepatitis CViral LoadSustained virological responseHeart DiseaseTreatment OutcomeItaly030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleViral loadHumanAdultmedicine.medical_specialtyHeart DiseasesLogistic ModelHepatitis C virusLiver CirrhosiAlpha interferonIL28B polymorphismAntiviral AgentsPolymorphism Single Nucleotide03 medical and health sciencesIron liver overloadInternal medicineRibavirinmedicineHumansRetrospective StudiesAntiviral AgentCirrhosiHepaciviruPeg-interferonHepatologybusiness.industryInterleukinsRibavirinbeta-ThalassemiaInterferon-alphaHepatitis C ChronicInterleukinmedicine.diseaseLogistic Models030104 developmental biologychemistryMultivariate AnalysisImmunologyInterferonsbusinessHepatitis C viru
researchProduct

The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success

2020

Contains fulltext : 229341.pdf (Publisher’s version ) (Open Access) INTRODUCTION: Numerous pharmacological compounds that target the different molecular targets involved in the pathobiology of nonalcoholic steatohepatitis (NASH) are currently in clinical testing. So far, there are no regulatory approvals. AREAS COVERED: This paper sheds light on the molecular pathways involved in NASH and the drugs targeting these pathways. We have identified 10 compounds whose clinical development program has been halted. Moreover, we explore early phase clinical trials and dissect the reasons for termination of development. EXPERT OPINION: The main goal of NASH pharmacotherapy is to halt or reverse hepati…

Liver Cirrhosis0301 basic medicineNonalcoholic steatohepatitisAnti-Inflammatory AgentsPhases of clinical researchBioinformaticsdigestive system03 medical and health sciences0302 clinical medicineDrug DevelopmentNon-alcoholic Fatty Liver DiseasemedicineAnimalsHumansPharmacology (medical)Molecular Targeted TherapyPharmacologybusiness.industryFatty liverGeneral Medicinemedicine.diseasedigestive system diseasesRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]030104 developmental biologyDrug development030220 oncology & carcinogenesisMolecular targetsbusinessExpert Opinion on Investigational Drugs
researchProduct

Extracellular Matrix Molecular Remodeling in Human Liver Fibrosis Evolution

2016

Chronic liver damage leads to pathological accumulation of ECM proteins (liver fibrosis). Comprehensive characterization of the human ECM molecular composition is essential for gaining insights into the mechanisms of liver disease. To date, studies of ECM remodeling in human liver diseases have been hampered by the unavailability of purified ECM. Here, we developed a decellularization method to purify ECM scaffolds from human liver tissues. Histological and electron microscopy analyses demonstrated that the ECM scaffolds, devoid of plasma and cellular components, preserved the three-dimensional ECM structure and zonal distribution of ECM components. This method has been then applied on 57 l…

Liver Cirrhosis0301 basic medicineProteomicsPathologyProteomeBiopsylcsh:MedicineHepacivirusMatrix (biology)ProteomicsBiochemistryExtracellular matrixMiceLiver disease0302 clinical medicineFibrosisSettore BIO/13 - Biologia ApplicataMedicine and Health Scienceslcsh:Scienceliver fibrosisExtracellular Matrix ProteinsMultidisciplinaryDecellularizationAnimals; Extracellular Matrix; Hepacivirus; Humans; Liver; Liver Cirrhosis; Mice; Proteome; Proteomics; Tissue Scaffolds; Disease ProgressionTissue ScaffoldsChemistryLiver DiseasesLiver030220 oncology & carcinogenesisProteomeDisease ProgressionCellular Structures and OrganellesAnatomyliver fibrosis; extracellular matrix; proteomicsResearch Articlemedicine.medical_specialtyHistologySettore BIO/06extracellular matrixSurgical and Invasive Medical ProceduresGastroenterology and HepatologyScaffold03 medical and health sciencesmedicineAnimalsHumansHuman liverlcsh:RBiology and Life SciencesProteinsCell Biologymedicine.diseaseFibrosisLiver Fibrosi030104 developmental biologyLiver Fibrosis; Scaffold; Proteomicslcsh:QCollagensDevelopmental Biology
researchProduct